VBCR - April 2018, Vol 7, No 1
“Although the improvement among all health care providers is encouraging, opportunities exist to further increase counseling for exercise among adults with arthritis,” wrote Jennifer Hootman, PhD, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, and colleagues.
The American College of Rheumatology has updated its position on the use of biosimilars and now advises healthcare providers and clinicians to “incorporate biosimilars, where appropriate, into regimens to treat patients with rheumatologic diseases.”
“Our study, to our knowledge, is the first population-based study that investigates the association between working in cold environment and risk of developing RA among healthy individuals,” wrote Pingling Zeng, PhD, Institute of Environmental Medicine, Karolinska University, Stockholm, Sweden, and colleagues.
Results from a recent study demonstrated that myeloablative autologous stem-cell transplantation improved outcomes in patients with severe scleroderma, providing longer-term benefit, superior event-free survival, and overall survival compared with 12 months of cyclophosphamide.
A post hoc analysis of the recent OPTIMA trial showed that treatment-naïve patients with early rheumatoid arthritis treated with methotrexate monotherapy achieved good clinical outcomes compared with those who initiated therapy with methotrexate plus adalimumab.
Biologic disease-modifying antirheumatic drugs have been the cornerstone of therapy for patients with rheumatoid arthritis (RA) for more than a decade. Although highly effective, these therapies can be expensive and access to them may be limited for some patients.
Using Preference Phenotypes to Enhance Communication, Facilitate Treatment Decision-Making, and Personalize Care
Washington, DC—On March 7, 2018, FDA Commissioner Scott Gottlieb, MD, delivered a speech to attendees of the America’s Health Insurance Plans National Health Policy Conference that called out pharmacy benefit managers (PBMs) for their role in disincentivizing biosimilar development.
Page 1 of 2
Results 1 - 10 of 13
Results 1 - 10 of 13